{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:01:07Z","timestamp":1791252067902,"version":"4.1.0"},"reference-count":97,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2010,6,29]],"date-time":"2010-06-29T00:00:00Z","timestamp":1277769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therap Adv Gastroenterol"],"published-print":{"date-parts":[[2010,7]]},"abstract":"<jats:p>Although biologic agents directed against tumor necrosis factor alpha (TNF\u03b1) continue to be an effective therapeutic strategy for patients with inflammatory bowel disease (IBD), approximately 30% of patients with Crohn\u2019s disease (CD) who are refractory to standard treatment do not respond to induction therapy with TNF\u03b1 inhibitors and, of those who initially respond, 50% or more cease to respond within a year. Moreover, their use can be associated with significant safety issues. Clearly, there is a need to target alternative pathways involved in the inflammatory process. IBD is driven by the trafficking of lymphocytes from the circulation into the gut tissue that is mediated by adhesive interactions between the lymphocytes and endothelial cells. The adhesion molecules involved represent attractive targets for the development of new therapeutics which should aid in the resolution of existing inflammation, prevent recurrence of inflammation, and may potentially lead to long-term control of disease. In this article we review current opportunities and challenges facing anti-adhesion therapy in IBD, and discusses recent clinical development efforts that have focused on having an impact on two particular adhesive interactions: \u03b1<jats:sub>4<\/jats:sub>-integrin\/MAdCAM-1 and \u03b2<jats:sub>2<\/jats:sub>-integrin\/ICAM-1. Of particular interest is natalizumab, a humanized monoclonal antibody against human \u03b1<jats:sub>4<\/jats:sub>integrin that is approved for the treatment of patients with moderately-to-severely active CD and evidence of active inflammation. This agent represents an efficacious therapeutic option for patients who do not respond to, or have failed, a TNF-\u03b1 inhibitor.<\/jats:p>","DOI":"10.1177\/1756283x10373176","type":"journal-article","created":{"date-parts":[[2010,6,29]],"date-time":"2010-06-29T10:08:34Z","timestamp":1277806114000},"page":"239-258","source":"Crossref","is-referenced-by-count":93,"title":["Review: Anti-adhesion molecule therapy for inflammatory bowel disease"],"prefix":"10.1177","volume":"3","author":[{"given":"Subrata","family":"Ghosh","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, University of Calgary, 3280 Hospital Drive NW, Calgary, AB, Canada T2N 4N,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remo","family":"Panaccione","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Clinic, Gastroenterology Training Program; University of Calgary, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2010,6,29]]},"reference":[{"key":"atypb1","first-page":"S20","volume":"7","author":"Abreu, M.T.","year":"2007","journal-title":"Rev Gastroenterol Disord"},{"key":"atypb2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.02.085"},{"key":"atypb3","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70224-6"},{"key":"atypb4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60750-8"},{"key":"atypb5","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1242\/jcs.111.9.1165","volume":"111","author":"Bayless, K.J.","year":"1998","journal-title":"J Cell Sci"},{"key":"atypb6","doi-asserted-by":"crossref","first-page":"P130","DOI":"10.1191\/1352458502ms776oa","volume":"8","author":"Bennett, D.","year":"2002","journal-title":"Mult Scler"},{"key":"atypb7","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(95)90491-3"},{"key":"atypb8","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200510000-00006"},{"key":"atypb9","doi-asserted-by":"publisher","DOI":"10.1006\/clin.1997.4462"},{"key":"atypb10","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.11.040193.004003"},{"key":"atypb11","volume-title":"TYSABRI (natalizumab) Advisory Committee Briefing Document","author":"Biogen Idec and Elan Pharmaceuticals","year":"2007"},{"key":"atypb12","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109538200"},{"key":"atypb13","first-page":"97","volume":"151","author":"Briskin, M.","year":"1997","journal-title":"Am J Path"},{"key":"atypb14","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.29568"},{"key":"atypb15","doi-asserted-by":"publisher","DOI":"10.1126\/science.279.5349.381"},{"key":"atypb16","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.134.1.255"},{"key":"atypb17","doi-asserted-by":"publisher","DOI":"10.1038\/nri2340"},{"key":"atypb18","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.05.006"},{"key":"atypb19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904492"},{"key":"atypb20","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.11.041"},{"key":"atypb21","doi-asserted-by":"publisher","DOI":"10.1016\/S1054-3589(08)60070-8"},{"key":"atypb22","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.045294"},{"key":"atypb23","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20453"},{"key":"atypb24","volume-title":"TYSABRI\u00ae (natalizumab) prescribing information","author":"Elan Pharmaceuticals and Biogen Idec","year":"2010"},{"key":"atypb25","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-004-0709-y"},{"key":"atypb26","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(00)85637-1"},{"key":"atypb27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.06.007"},{"key":"atypb28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042982"},{"key":"atypb29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01508.x"},{"issue":"2","key":"atypb30","first-page":"A22","volume":"56","author":"Ghosh, S.","year":"2007","journal-title":"Gut"},{"key":"atypb31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020732"},{"key":"atypb32","doi-asserted-by":"publisher","DOI":"10.1021\/jm060031q"},{"key":"atypb33","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.26260"},{"key":"atypb34","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200608000-00013"},{"key":"atypb35","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1999.00985.x"},{"key":"atypb36","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.4049\/jimmunol.152.7.3282","volume":"152","author":"Hamann, A.","year":"1994","journal-title":"J Immunol"},{"key":"atypb37","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"atypb38","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.11.030"},{"key":"atypb39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.1990.tb00561.x"},{"key":"atypb40","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1996.v111.pm8898653"},{"key":"atypb41","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1996.v110.pm8613051"},{"key":"atypb42","doi-asserted-by":"publisher","DOI":"10.1097\/01.mpg.0000252191.05170.e7"},{"key":"atypb43","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(92)90115-S"},{"key":"atypb44","first-page":"18S","volume":"92","author":"Irvine, E.J.","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"atypb45","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.04.075"},{"key":"atypb46","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0022-3565(24)38885-8","volume":"295","author":"Kato, S.","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"atypb47","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000341766.59028.9d"},{"key":"atypb48","doi-asserted-by":"publisher","DOI":"10.1016\/0165-5728(94)00165-K"},{"key":"atypb49","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-0934(03)00043-0"},{"key":"atypb50","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.10450"},{"key":"atypb51","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(91)90393-D"},{"key":"atypb52","doi-asserted-by":"publisher","DOI":"10.3233\/HAB-1997-8102"},{"key":"atypb53","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1521-4141(199811)28:11<3605::AID-IMMU3605>3.0.CO;2-J"},{"key":"atypb54","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200109098"},{"key":"atypb55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810316"},{"key":"atypb56","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117519"},{"key":"atypb57","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00266.2007"},{"key":"atypb58","volume-title":"Millennium announces phase II data for MLN02 in Crohn\u2019s disease. Millennium Investor Relations News Release, 16 September 2002","author":"Millennium Pharmaceuticals","year":"2002"},{"key":"atypb59","volume-title":"Millennium resumes clinical program for MLN0002. Millennium Investor Relations News Release, 17 May 2007","author":"Millennium Pharmaceuticals","year":"2007"},{"key":"atypb60","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.02909.x"},{"key":"atypb61","doi-asserted-by":"publisher","DOI":"10.1080\/02648725.1992.10647886"},{"key":"atypb62","first-page":"OP-G-180","author":"Panaccione, R.","year":"2006","journal-title":"Abstract presented at United European Gastroenterology Week (UEGW)"},{"key":"atypb63","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00059.2007"},{"key":"atypb64","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31570"},{"key":"atypb65","volume-title":"Presented at: American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course; 23-28 October 2009","author":"Pepio, A."},{"key":"atypb66","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116575"},{"key":"atypb67","doi-asserted-by":"publisher","DOI":"10.1016\/S0923-2494(93)80057-6"},{"key":"atypb68","volume-title":"Presented at: Digestive Disease Week; 19-24 May 2007","author":"Present, D."},{"key":"atypb69","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.59.12.1930"},{"key":"atypb70","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20501"},{"key":"atypb71","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043335"},{"key":"atypb72","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067594"},{"key":"atypb73","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-12-200706190-00159"},{"key":"atypb74","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.08703.x"},{"key":"atypb75","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20014"},{"key":"atypb76","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.24015"},{"key":"atypb77","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.8.9.1417"},{"key":"atypb78","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.3780164"},{"key":"atypb79","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90337-9"},{"key":"atypb80","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2004.02402.x"},{"key":"atypb81","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.20.100301.064816"},{"key":"atypb82","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.64.2.169"},{"key":"atypb83","volume-title":"Presented at: Digestive Disease Week; 30 May-4 June 2009","author":"Takazoe, M."},{"key":"atypb84","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.03.024"},{"key":"atypb85","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00423.2004"},{"key":"atypb86","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.02910.x"},{"key":"atypb87","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2007.145698"},{"key":"atypb88","volume-title":"Presented at: The Congress of European Crohn\u2019s and Colitis Organization; 28 February-1 March 2008","author":"Vermeire, S."},{"key":"atypb89","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.1999.79.1.181"},{"key":"atypb90","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200010053431407"},{"key":"atypb91","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.072793"},{"key":"atypb92","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.11.001"},{"key":"atypb93","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(98)70418-4"},{"key":"atypb94","doi-asserted-by":"publisher","DOI":"10.1136\/gut.51.1.30"},{"key":"atypb95","doi-asserted-by":"publisher","DOI":"10.1006\/excr.2000.5002"},{"key":"atypb96","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0804460"},{"key":"atypb97","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054693"}],"container-title":["Therapeutic Advances in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1756283X10373176","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1756283X10373176","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T05:37:28Z","timestamp":1740893848000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1756283X10373176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,29]]},"references-count":97,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["10.1177\/1756283X10373176"],"URL":"https:\/\/doi.org\/10.1177\/1756283x10373176","relation":{},"ISSN":["1756-2848","1756-2848"],"issn-type":[{"value":"1756-2848","type":"print"},{"value":"1756-2848","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,29]]}}}